mTOR pathway in colorectal cancer: an update
The mammalian target of rapamycin (mTOR) has emerged as a potential target for drug development, particularly due to the fact that it plays such a crucial role in cancer biology. In addition, next-generation mTOR inhibitors have become available, marking an exciting new phase in mTOR-based therapy....
Gespeichert in:
| Veröffentlicht in: | Oncotarget 2014-01, Vol.5 (1), p.49-66 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 66 |
|---|---|
| container_issue | 1 |
| container_start_page | 49 |
| container_title | Oncotarget |
| container_volume | 5 |
| creator | Francipane, Maria Giovanna Lagasse, Eric |
| description | The mammalian target of rapamycin (mTOR) has emerged as a potential target for drug development, particularly due to the fact that it plays such a crucial role in cancer biology. In addition, next-generation mTOR inhibitors have become available, marking an exciting new phase in mTOR-based therapy. However, the verdict on their therapeutic effectiveness remains unclear. Here we review phosphatidylinositol-3-kinase (PI3K)/Akt/mTOR signaling as one of the primary mechanisms for sustaining tumor outgrowth and metastasis, recent advances in the development of mTOR inhibitors, and current studies addressing mTOR activation/inhibition in colorectal cancer (CRC). We will also discuss our recent comparative study of different mTOR inhibitors in a population of colon cancer stem cells (CSCs), and current major challenges for achieving individualized drug therapy using kinase inhibitors. |
| doi_str_mv | 10.18632/oncotarget.1548 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3960188</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1508425375</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-4d6c518aae2e6df2a4235fcb34686ed405a40d3a17139607ef790152629dfe663</originalsourceid><addsrcrecordid>eNpVkM1Lw0AQxRdRrNTePUmOHkzd72w8CFL8gkJB6nmZbjZtJMnG3UTpf29qa61zmYF57zfDQ-iC4DFRktEbVxvXgl_adkwEV0fojKQ8jakQ7PhgHqBRCO-4L8ETRdNTNKCcpSzB6gxdV_PZa9RAu_qCdVTUkXGl89a0UEYGamP9bQR11DUZtPYcneRQBjva9SF6e3yYT57j6ezpZXI_jQ2XtI15Jo0gCsBSK7OcAqdM5GbBuFTSZhwL4DhjQBLCUokTmycpJoJKmma5lZIN0d2W23SLymbG1q2HUje-qMCvtYNC_9_UxUov3afe4IhSPeBqB_Duo7Oh1VURjC1LqK3rgiYCK04FS0QvxVup8S4Eb_P9GYL1T876L2e9ybm3XB6-tzf8psq-AQJieyE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1508425375</pqid></control><display><type>article</type><title>mTOR pathway in colorectal cancer: an update</title><source>MEDLINE</source><source>PubMed Central Open Access</source><source>PubMed Central</source><source>Free E- Journals</source><source>EZB Electronic Journals Library</source><creator>Francipane, Maria Giovanna ; Lagasse, Eric</creator><creatorcontrib>Francipane, Maria Giovanna ; Lagasse, Eric</creatorcontrib><description>The mammalian target of rapamycin (mTOR) has emerged as a potential target for drug development, particularly due to the fact that it plays such a crucial role in cancer biology. In addition, next-generation mTOR inhibitors have become available, marking an exciting new phase in mTOR-based therapy. However, the verdict on their therapeutic effectiveness remains unclear. Here we review phosphatidylinositol-3-kinase (PI3K)/Akt/mTOR signaling as one of the primary mechanisms for sustaining tumor outgrowth and metastasis, recent advances in the development of mTOR inhibitors, and current studies addressing mTOR activation/inhibition in colorectal cancer (CRC). We will also discuss our recent comparative study of different mTOR inhibitors in a population of colon cancer stem cells (CSCs), and current major challenges for achieving individualized drug therapy using kinase inhibitors.</description><identifier>ISSN: 1949-2553</identifier><identifier>EISSN: 1949-2553</identifier><identifier>DOI: 10.18632/oncotarget.1548</identifier><identifier>PMID: 24393708</identifier><language>eng</language><publisher>United States: Impact Journals LLC</publisher><subject>Animals ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - genetics ; Colorectal Neoplasms - metabolism ; Humans ; Molecular Targeted Therapy ; Precision Medicine ; Review ; Signal Transduction ; TOR Serine-Threonine Kinases - antagonists & inhibitors ; TOR Serine-Threonine Kinases - genetics ; TOR Serine-Threonine Kinases - metabolism</subject><ispartof>Oncotarget, 2014-01, Vol.5 (1), p.49-66</ispartof><rights>Copyright: © 2014 Francipane and Lagasse 2014</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-4d6c518aae2e6df2a4235fcb34686ed405a40d3a17139607ef790152629dfe663</citedby><cites>FETCH-LOGICAL-c462t-4d6c518aae2e6df2a4235fcb34686ed405a40d3a17139607ef790152629dfe663</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960188/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960188/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24393708$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Francipane, Maria Giovanna</creatorcontrib><creatorcontrib>Lagasse, Eric</creatorcontrib><title>mTOR pathway in colorectal cancer: an update</title><title>Oncotarget</title><addtitle>Oncotarget</addtitle><description>The mammalian target of rapamycin (mTOR) has emerged as a potential target for drug development, particularly due to the fact that it plays such a crucial role in cancer biology. In addition, next-generation mTOR inhibitors have become available, marking an exciting new phase in mTOR-based therapy. However, the verdict on their therapeutic effectiveness remains unclear. Here we review phosphatidylinositol-3-kinase (PI3K)/Akt/mTOR signaling as one of the primary mechanisms for sustaining tumor outgrowth and metastasis, recent advances in the development of mTOR inhibitors, and current studies addressing mTOR activation/inhibition in colorectal cancer (CRC). We will also discuss our recent comparative study of different mTOR inhibitors in a population of colon cancer stem cells (CSCs), and current major challenges for achieving individualized drug therapy using kinase inhibitors.</description><subject>Animals</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - genetics</subject><subject>Colorectal Neoplasms - metabolism</subject><subject>Humans</subject><subject>Molecular Targeted Therapy</subject><subject>Precision Medicine</subject><subject>Review</subject><subject>Signal Transduction</subject><subject>TOR Serine-Threonine Kinases - antagonists & inhibitors</subject><subject>TOR Serine-Threonine Kinases - genetics</subject><subject>TOR Serine-Threonine Kinases - metabolism</subject><issn>1949-2553</issn><issn>1949-2553</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkM1Lw0AQxRdRrNTePUmOHkzd72w8CFL8gkJB6nmZbjZtJMnG3UTpf29qa61zmYF57zfDQ-iC4DFRktEbVxvXgl_adkwEV0fojKQ8jakQ7PhgHqBRCO-4L8ETRdNTNKCcpSzB6gxdV_PZa9RAu_qCdVTUkXGl89a0UEYGamP9bQR11DUZtPYcneRQBjva9SF6e3yYT57j6ezpZXI_jQ2XtI15Jo0gCsBSK7OcAqdM5GbBuFTSZhwL4DhjQBLCUokTmycpJoJKmma5lZIN0d2W23SLymbG1q2HUje-qMCvtYNC_9_UxUov3afe4IhSPeBqB_Duo7Oh1VURjC1LqK3rgiYCK04FS0QvxVup8S4Eb_P9GYL1T876L2e9ybm3XB6-tzf8psq-AQJieyE</recordid><startdate>20140115</startdate><enddate>20140115</enddate><creator>Francipane, Maria Giovanna</creator><creator>Lagasse, Eric</creator><general>Impact Journals LLC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20140115</creationdate><title>mTOR pathway in colorectal cancer: an update</title><author>Francipane, Maria Giovanna ; Lagasse, Eric</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-4d6c518aae2e6df2a4235fcb34686ed405a40d3a17139607ef790152629dfe663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Animals</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - genetics</topic><topic>Colorectal Neoplasms - metabolism</topic><topic>Humans</topic><topic>Molecular Targeted Therapy</topic><topic>Precision Medicine</topic><topic>Review</topic><topic>Signal Transduction</topic><topic>TOR Serine-Threonine Kinases - antagonists & inhibitors</topic><topic>TOR Serine-Threonine Kinases - genetics</topic><topic>TOR Serine-Threonine Kinases - metabolism</topic><toplevel>online_resources</toplevel><creatorcontrib>Francipane, Maria Giovanna</creatorcontrib><creatorcontrib>Lagasse, Eric</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncotarget</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Francipane, Maria Giovanna</au><au>Lagasse, Eric</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>mTOR pathway in colorectal cancer: an update</atitle><jtitle>Oncotarget</jtitle><addtitle>Oncotarget</addtitle><date>2014-01-15</date><risdate>2014</risdate><volume>5</volume><issue>1</issue><spage>49</spage><epage>66</epage><pages>49-66</pages><issn>1949-2553</issn><eissn>1949-2553</eissn><abstract>The mammalian target of rapamycin (mTOR) has emerged as a potential target for drug development, particularly due to the fact that it plays such a crucial role in cancer biology. In addition, next-generation mTOR inhibitors have become available, marking an exciting new phase in mTOR-based therapy. However, the verdict on their therapeutic effectiveness remains unclear. Here we review phosphatidylinositol-3-kinase (PI3K)/Akt/mTOR signaling as one of the primary mechanisms for sustaining tumor outgrowth and metastasis, recent advances in the development of mTOR inhibitors, and current studies addressing mTOR activation/inhibition in colorectal cancer (CRC). We will also discuss our recent comparative study of different mTOR inhibitors in a population of colon cancer stem cells (CSCs), and current major challenges for achieving individualized drug therapy using kinase inhibitors.</abstract><cop>United States</cop><pub>Impact Journals LLC</pub><pmid>24393708</pmid><doi>10.18632/oncotarget.1548</doi><tpages>18</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1949-2553 |
| ispartof | Oncotarget, 2014-01, Vol.5 (1), p.49-66 |
| issn | 1949-2553 1949-2553 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3960188 |
| source | MEDLINE; PubMed Central Open Access; PubMed Central; Free E- Journals; EZB Electronic Journals Library |
| subjects | Animals Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Colorectal Neoplasms - metabolism Humans Molecular Targeted Therapy Precision Medicine Review Signal Transduction TOR Serine-Threonine Kinases - antagonists & inhibitors TOR Serine-Threonine Kinases - genetics TOR Serine-Threonine Kinases - metabolism |
| title | mTOR pathway in colorectal cancer: an update |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T11%3A20%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=mTOR%20pathway%20in%20colorectal%20cancer:%20an%20update&rft.jtitle=Oncotarget&rft.au=Francipane,%20Maria%20Giovanna&rft.date=2014-01-15&rft.volume=5&rft.issue=1&rft.spage=49&rft.epage=66&rft.pages=49-66&rft.issn=1949-2553&rft.eissn=1949-2553&rft_id=info:doi/10.18632/oncotarget.1548&rft_dat=%3Cproquest_pubme%3E1508425375%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1508425375&rft_id=info:pmid/24393708&rfr_iscdi=true |